Atherosclerosis News and Research

RSS

Atherosclerosis is the progressive buildup of plaque - the fatty deposits and other cells - in the inner walls of the arteries. The condition is a consequence of elevated cholesterol and for many it's a silent disease, with no visible signs or symptoms. The disease can begin in early adulthood and continues to progress for the rest of a person's life. Despite the serious nature of atherosclerosis, many people do not understand how it develops and progresses.

Studies use three genes to reprogram fibroblasts into myocytes

The latest research developments to reprogram scar tissue resulting from myocardial infarction (MI) into viable heart muscle cells, were presented at the Frontiers in CardioVascular Biology (FCVB) 2012 meeting, held 30 March to 1 April at the South Kensington Campus of Imperial College in London.

2 Apr 2012

Nasal spray to prevent fat and plaque built up in the heart on the horizon

Researchers found a treatment that was much more effective in removing fat from arteries than established methods. The vaccine can be given as an injection or in a slightly different form as a nasal spray. A trial on 144 heart disease sufferers is under way in the US and Canada.

1 Apr 2012

Starvation during childhood may increase risk of heart complications

Russians born during the Leningrad Siege in World War II, which was responsible for some of the greatest losses of civilian life in history, are giving scientists new strategies to identify people who experienced intrauterine growth restriction (IUGR) and starvation during childhood at greatest risk of developing long term heart complications.

31 Mar 2012

AlphaCore Pharma commences ACP-501 Phase 1 study in coronary arterial disease

AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease.

31 Mar 2012

Spherix 2011 net loss decreases to $3.5 million

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today reported financial results for the year ended December 31, 2011, and recent and upcoming business highlights.

29 Mar 2012

Hyperinsulinemia itself not a cause of atherosclerosis

A number of studies have shown that excess insulin circulating in the bloodstream is a major independent risk factor for cardiovascular disease. However, a new study from Joslin Diabetes Center finds that this condition, called hyperinsulinemia, is itself not a cause of atherosclerosis.

28 Mar 2012

UT Southwestern researcher wins prestigious award from International Atherosclerosis Society

Dr. Helen Hobbs, a preeminent researcher on the genetics of cholesterol metabolism at UT Southwestern Medical Center, has won a prestigious award from the International Atherosclerosis Society.

28 Mar 2012

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

An experimental drug that acts in a novel way to lower cholesterol proved even more effective than statins and had few undesirable side effects, newly released data shows. The drug acts by modifying the way cholesterol levels are naturally controlled. A protein produced in the liver helps limit the amount of LDL, or “bad” cholesterol, that liver cells can remove from the bloodstream. The new drug, called REGN727, is a monoclonal antibody, made in a laboratory, that blocks the action of that protein.

27 Mar 2012

CCTA can safely and rapidly identify candidates for discharge from EDs

Coronary CT angiography (CCTA) -- a non-invasive way to look inside arteries that supply blood to the heart -- can quickly and reliably determine which patients complaining of chest pain at an emergency department can safely be sent home, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

Lowering LDL at younger age can reduce risk of CHD

Coronary atherosclerosis - a hardening of the arteries due to a build-up of fat and cholesterol - can lead to heart attacks and other forms of coronary heart disease (CHD). Lowering low-density lipoprotein (LDL), or "bad" cholesterol, reduces the risk of CHD, and researchers found that lowering LDL beginning early in life resulted in a three-fold greater reduction in the risk of CHD than treatment with a statin started later in life, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

Pregnancy raises risk of heart attacks

According to a new study pregnancy and related hormonal changes that continue 12 weeks after giving birth increase a woman's risk of heart attack. Although the likelihood of having a heart attack during pregnancy is very low - just 1 in every 16,000 deliveries - it is still 3 to 4 times higher than non-pregnant women of the same age.

26 Mar 2012

Raisins may help lower blood pressure

If you have slightly higher than normal blood pressure - known as prehypertension - consider eating a handful of raisins. New data suggest that, among individuals with mild increases in blood pressure, the routine consumption of raisins (three times a day) may significantly lower blood pressure, especially when compared to eating other common snacks, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

26 Mar 2012

Promising results from Esperion ETC-1002 Phase 2 clinical trial for dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced positive results from a Phase 2 clinical trial for ETC-1002.

26 Mar 2012

Results from Merck's vorapaxar study on cardiovascular events

Researchers today presented and published results from the TRA-2P (Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) TIMI 50 study of vorapaxar, Merck's investigational anti-thrombotic medicine, in patients with a prior history of cardiovascular events or disease.

26 Mar 2012

PROLOR commences hGH-CTP Phase II trial in children with GHD

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency.

20 Mar 2012

Soy-based S-equol lowers HbA1c, LDL cholesterol and improves vascular stiffness

A 12-week treatment of the fermented soy germ-based nutritional supplement containing S-equol significantly lowered hemoglobin A1c (HbA1c), LDL cholesterol and improved vascular stiffness, all factors that occur as part of metabolic syndrome, according to a first-of-its-kind peer-reviewed study reported in a poster at the Women's Health 2012 annual meeting.

19 Mar 2012

Positive data from VBL Therapeutics' VB-201 Phase 2 study on psoriasis, atherosclerosis

VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that a Phase 2 sub-study of VB-201 in moderate to severe psoriasis patients with cardiovascular risk has successfully achieved its primary endpoint demonstrating a statistically significant reduction in vascular inflammation associated with atherosclerotic lesions as measured by PET-CT imaging.

17 Mar 2012

diaDexus fourth quarter total revenues increase 48% to $4.9 million

diaDexus, Inc.a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced financial results for the 2011 fourth quarter and year-end.

16 Mar 2012

Anti-inflammatory drugs may offer novel treatment for CHD

A large international study indicates that anti-inflammatory drugs may become a new tool for preventing and treating coronary heart disease (CHD), the leading global cause of death.

15 Mar 2012

Researchers unlock mystery of how an inflammatory molecule is produced in the body

Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people.

12 Mar 2012